Background. Previous studies suggest that Helicobacter cinaedi can cause recurrent bacteremia. In this study, we elucidated the risk factors for recurrent H. cinaedi bacteremia and explored the efficacy of selective digestive decontamination (SDD) as a preventive measure.
Helicobacter cinaedi is a gram-negative spiral bacillus that causes enteric or bloodstream infections. It was first isolated from rectal cultures obtained from homosexual men [1, 2] . Since 2000, an increasing number of cases of H. cinaedi bacteremia have been reported, especially in human immunodeficiency virus (HIV)-negative immunocompromised patients. In our previous study, H. cinaedi was detected in 2.2% of blood culture-positive cases [3] . Previous studies suggest that H. cinaedi bacteremia can recur [3] [4] [5] [6] [7] [8] . However, there are no available data on the risk factors and treatment strategies for recurrent bacteremia.
In a recent study, we demonstrated that bacterial translocation from the intestinal tract could represent one route of H. cinaedi bacteremia [9] . Therefore, we hypothesized that selective digestive decontamination (SDD) with oral kanamycin, which is nonabsorbable in the gastrointestinal tract, was a potential strategy for reducing the rate of recurrence. SDD has been used to prevent severe infections and reduce mortality, particularly in critically ill patients [10] , including to prevent bacterial translocation following burns [11] . Moreover, a recent case report suggested that SDD with oral kanamycin could be used successfully for recurrent Helicobacter fennelliae bacteremia [12] .
In this study, we aimed to elucidate the risk factors for recurrent H. cinaedi bacteremia and explore the efficacy of SDD as a preventive measure.
METHODS
The medical records of all patients diagnosed with H. cinaedi bacteremia between March 2009 and December 2016 at Toranomon Hospital (868 beds; Tokyo, Japan) and Toranomon Hospital Kajigaya (300 beds; Kanagawa, Japan) were retrospectively reviewed. Blood culture samples were processed using the BACTEC 9240 and BACTEC FX systems (Becton Dickinson Microbiology Systems, Sparks, Maryland). All samples were routinely monitored for 7 days. If blood cultures were obtained from patients who had previous H. cinaedi bacteremia and H. cinaedi infection was again suspected, bottles were blindly subcultured aerobically and anaerobically on M A J O R A R T I C L E day 7 and monitored for another 7 days. A microaerobic culture using AnaeroPack-MicroAero (Mitsubishi Gas Chemical Co., Inc., Tokyo, Japan; oxygen level, 6%-12%; carbon dioxide level, 5%-8%) was conducted with chocolate II agar (Nippon Becton Dickinson Co., Ltd., Tokyo, Japan) and trypticase soy agar II with 5% sheep blood (Nippon Becton Dickinson Co., Ltd.) at 35°C for 7 days to identify H. cinaedi infection when positive blood cultures and gram-negative spiral bacillus were found. Microaerobic cultures of stool samples for detecting only H. cinaedi were conducted in modified Skirrow medium EX (Nissui Pharmaceutical Co., Ltd.) at 35°C for 7 days. Helicobacter cinaedi was identified using gyrB-targeted polymerase chain reaction methods that are specific to only H. cinaedi (195 bp; forward primer: 5′-AGGGATTCCACAAAGTGAGC-3′; reverse primer: 5′-TCTTGTCCTGTGCGTTCATC-3′) [13] .
Chronic kidney disease was defined as a serum creatinine concentration of ≥2.0 mg/dL. Chronic liver disease was defined as liver cirrhosis or chronic hepatitis B or C infection. Chronic respiratory diseases were defined as diseases of the airways and other structures of the lung, such as chronic obstructive pulmonary disease, bronchial asthma, interstitial pneumonia, and bronchiectasis. Cardiovascular device meant the presence of a pacemaker, an internal cardiac defibrillator, a prosthetic valve, or an endovascular device. Patients receiving anticancer chemotherapy were defined as those who received systemic therapy within 3 months prior to the first episode of H. cinaedi bacteremia. Systemic steroid administration was defined as ≥1 dose of oral or intravenous steroids within 30 days prior to the first episode of H. cinaedi bacteremia. The Charlson comorbidity index based on the day of the index culture was calculated [14] . The Pitt bacteremia score was used to evaluate the severity of H. cinaedi bacteremia [15] . Neutropenia was defined as an absolute neutrophil count of <500 /mm 3 . Severity of diarrhea was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (v4.03) [16] . Penicillin-, cephem-, carbapenem-, and fluoroquinolone-containing regimens were defined as ≥7 days of antibiotic treatment for H. cinaedi bacteremia. Recurrence was defined as a positive H. cinaedi blood culture of a specimen collected ≥2 days after clinical improvement and/or completion of a course of systemic antimicrobial therapy for H. cinaedi. The data obtained from the first episode of recurrent bacteremia were included in this study. The SDD protocol was defined as follows: oral kanamycin 2000 mg daily (500 mg 4 times/day or 1000 mg 2 times/day) in patients with normal renal function; a dose reduction was considered in patients with severe renal dysfunction. The duration of SDD was ≥7 days.
Recurrence was estimated using cumulative incidence analysis, with death treated as a competing risk. Gray's test and Fine-Gray regression were used to analyze recurrences. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. Variables with borderline significance on univariate analysis (Gray's test; P ≤ .15) were included in multivariate analysis (Fine-Gray proportional hazard regression). The full model was reduced to a final model by using a backward stepwise procedure in the multivariate analysis with a threshold of P ≤ . 15 Statistical analyses except for the proportional hazards assumption were performed with EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (R Foundation for Statistical Computing, Vienna, Austria). More precisely, it is a modified version of the R commander designed to add statistical functions that are frequently used in biostatistics [17] . The proportional hazards assumption was performed with SAS 9.4 software (SAS Institute Inc, Cary, North Carolina).
The human ethics review committees of Toranomon Hospital, Toranomon Hospital Kajigaya, and The University of Tokyo approved the study.
RESULTS

Characteristics of Patients With H. cinaedi Bacteremia
We identified 168 patients with H. cinaedi bacteremia. The median observation period of the patients after completing a course of systemic antimicrobial therapy for H. cinaedi was 422 (range, 1-2655) days. The clinical characteristics of the patients are listed in Table 1 .
There were 88 men and 80 women, with a median age of 66 (range, 26-88) years. The top 3 underlying diseases were chronic kidney disease in 52, including 25 undergoing hemodialysis; solid tumors in 48; and hematological malignancy in 40. Seven patients had no apparent underlying disease. We screened 127 patients for HIV-1/2 by enzyme-linked immunosorbent assay; all were HIV negative. On the day H. cinaedi bacteremia was detected, central venous catheters had been used in 13 patients, peripheral venous catheters in 58 patients, and cardiovascular devices had been inserted into 15 patients. Among the patients, 63 had received anticancer chemotherapy within 3 months and 82 had received systemic steroids within 30 days before the diagnosis of H. cinaedi bacteremia. Diarrhea was present in 18 patients.
The most frequent clinical symptom of the 168 patients with H. cinaedi bacteremia was cellulitis (54 cases). In most cases of cellulitis, erythema with a vague border and tenderness in the lower extremities were present. However, 78 patients presented with fever only, including 15 patients with febrile neutropenia.
We obtained stool samples from 114 patients; cultures from 58 of the 114 (51%) were positive for H. cinaedi. Of 114 stool samples, 97 (85%) were obtained after empirical antibiotic treatment was initiated. Stool samples obtained before empirical antibiotic treatment was initiated contained 14 of 17 (82%) H. cinaedi-positive cultures.
Treatment and Prognosis
Median duration of systemic antimicrobial treatment was 21 (range, 0-130) days. Various antimicrobial agents were administered in this study. A penicillin-containing regimen was administered in 103 patients, a cephem-containing regimen in 70, a carbapenem-containing regimen in 23, and a fluoroquinolone-containing regimen in 16. None of the patients received ≥2 antimicrobial agents simultaneously. The overall 30-day mortality rate of H. cinaedi bacteremia in this study was 6.0% (10/168).
Rate of Recurrent H. cinaedi Bacteremia
Recurrent bacteremia occurred in 34 patients (34/168, 20.2%). The 100-day cumulative incidence of recurrent bacteremia was 18.7% (12.2%-24.7%; Figure 1 ). Median time to recurrence after the completion of antibiotic treatment was 26 (range, 2-443) days.
Factors Associated With Recurrent Bacteremia
Univariate Analysis
In univariate analysis of the factors associated with recurrent bacteremia, anticancer chemotherapy within 3 months (HR, 3.75; 95% CI, 1.86-7.58; P < .001), systemic steroids within 30 days (HR, 3.79; 95% CI, 1.70-8.45; P = .0011), and hematological malignancy (HR, 3.18; 95% CI, 1.64-6.19; P < .001) were detected as risk factors (Table 2) .
Similar to the result of anticancer chemotherapy within 3 months, anticancer chemotherapy within 1 week, within 2 weeks, and within 1 month were detected as risk factors. Also, systemic steroids within 1 week and within 2 weeks and a cumulative dose of >700 mg of prednisone were detected as risk factors (Table 2) .
No significant differences in age, sex ratio, other underlying diseases, indwelling catheter, cardiovascular device, Pitt bacteremia score, Charlson comorbidity index, antimicrobial regimen, and duration of treatment were observed between the recurrence (n = 34) and the nonrecurrence (n = 134) groups. A tendency toward recurrent bacteremia was found in the subgroup that received fluoroquinolone-containing regimens, but this was not statistically significant (HR, 1.57; 95% CI, 0.60-4.12; P = .36). In addition, the subgroup that received antimicrobials for <21 days showed a high tendency toward recurrent bacteremia, but this was not statistically significant (HR, 1.80; 95% CI, 0.92-3.50; P = .08).
Multivariate Analysis
After variable selection using a backward stepwise procedure, multivariate analysis indicated that anticancer chemotherapy within 3 months (HR, 2.47; 95% CI, 1.19-5.12; P = .015) and systemic steroids within 30 days (HR, 2.40; 95% CI, 1.03-5.61; P = .044) were independent risk factors for recurrent bacteremia ( Table 2 ). The global test for lack of proportionality for time-varying covariate effects was not significant (P = .84).
Efficacy of SDD for Prevention of Recurrent Bacteremia
Of the 168 patients with H. cinaedi bacteremia, 47 were treated with SDD to prevent recurrence. SDD treatment had already been initiated on completion of a course of systemic antimicrobial therapy against H. cinaedi bacteremia in 42 patients. Five patients started SDD treatment after completing a course of systemic antimicrobials. Oral kanamycin dosages were as follows: 500 mg 4 times daily in 23 patients, 1000 mg 2 times daily in 15 patients, 500 mg 3 times daily in 5 patients, 500 mg 2 times daily in 1 patient, and 250 mg 3 times daily in 3 patients. Median duration of SDD was 21 (range, 7-77) days. A negative stool culture was confirmed after starting SDD in all cases. Recurrences 
DISCUSSION
To date, few studies have described cases of recurrent H. cinaedi bacteremia [3] [4] [5] [6] [7] [8] . To our knowledge, this study is the largest case series to describe recurrent H. cinaedi bacteremia. We revealed 3 major new findings: the 100-day cumulative incidence of recurrent H. cinaedi bacteremia, risk factors for recurrent bacteremia, and the efficacy of SDD for the prevention of recurrent bacteremia. The 100-day cumulative incidence rate of recurrent bacteremia was 18.7%. Although the data obtained from the first episode of recurrent bacteremia were included in this study, 3 patients had recurrent bacteremia on ≥2 occasions. The median Pitt bacteremia score was 0, and the mortality rate was low, although the recurrence rate was high. Clearly, it is important to establish a standard treatment strategy for H. cinaedi bacteremia.
We found that anticancer chemotherapy and systemic steroids were independent risk factors for recurrent bacteremia, while age, the Charlson comorbidity index, and the Pitt bacteremia score were not detected as risk factors. The route of H. cinaedi infection is rarely known, but it is often thought to be fecaloral because prior contact with animals has been reported in H. cinaedi-infected patients [8, 18] . Helicobacter cinaedi colonizes the gastrointestinal tract, and bacterial translocation leads to the development of bacteremia associated with mucosal damage [9, 19] . We confirmed that 58 of 114 (51%) stool cultures were positive for H. cinaedi. Furthermore, 14 of 17 (82%) stool cultures that were obtained before empirical antimicrobial treatment commenced were H. cinaedi-positive. Therefore, it is possible that most patients had H. cinaedi in the gastrointestinal tract.
The cause of recurrent bacteremia in specific cases is unknown. Because anticancer chemotherapy was found to be a risk factor for recurrent bacteremia, it is possible that these drugs damage the mucosal cells in the gastrointestinal tract. Diarrhea occurred in 18 patients in this study. There were no apparent relationships between specific anticancer regimens and the subsequent infections; however, all of the anticancer chemotherapies administered within 3 months, within 1 week, within 2 weeks, and within 1 month were detected as risk factors.
In addition, steroids can inhibit cellular immunity and the actions of neutrophils in the host. All systemic steroids within 30 days, within 1 week, within 2 weeks, and a cumulative dose of >700 mg of prednisone were detected as risk factors in this study. A recent study indicated that the short-term (within 30 days) and low-dose use (even a daily dose of <20 mg of prednisone) of oral corticosteroids were associated with increased rates of sepsis [20] . Another study reported the impact of a cumulative dose of prednisone on the subsequent infections [21] . The results of that study showed that the risk of prednisone therapy-associated infection complications was dose-dependent, with no increased risk in patients given cumulative doses of <700 mg [21] .
In contrast, the different antimicrobial regimens and durations of treatment were not risk factors for recurrent bacteremia. A tendency toward recurrent bacteremia was found in the subgroup that received fluoroquinolone-containing regimens, but this was not statistically significant. In general, the minimal inhibitory concentration (MIC) values of carbapenems, aminoglycosides, and tetracycline are relatively low for H. cinaedi strains, while those of penicillins and cephalosporins are moderate [22] . In contrast, H. cinaedi strains have well-known resistance to fluoroquinolones and macrolides, thus the MIC values are higher [22] . Together with our findings, this suggests that fluoroquinolone-containing regimens should be avoided in the treatment of H. cinaedi bacteremia. The subgroup that received antimicrobials for <21 days showed a high tendency toward recurrent bacteremia, but again this was not statistically significant. Based on the results of our study and some previous studies, which recommended long-term rather than short-term therapy, the appropriate duration of therapy could be ≥21 days [6, 8, 18] .
We hypothesized that SDD could reduce the rate of recurrent bacteremia. SDD is generally classified into 2 major methods as follows [10, 23] : 1, short course (4 days) of parenteral antimicrobials to control primary endogenous infections, and 2, topical and nonabsorbable antimicrobials, such as polymyxin E, tobramycin, and amphotericin B, to control secondary oropharyngeal and intestinal carriage and subsequent secondary endogenous infections. Our aim in using SDD in this study was to eradicate H. cinaedi in the gastrointestinal tract and prevent recurrent bacteremia. The MIC value of kanamycin, which is nonabsorbable in the gastrointestinal tract, is relatively low for H. cinaedi [8, 24] . In our study, Gray's test showed that SDD might reduce the rate of recurrence (HR, 0.46), although this result was not statistically significant (P = .11). In the proportional hazard modeling analysis with the start of SDD as a time-dependent covariate, SDD reduced the rate of recurrence of H. cinaedi bacteremia (HR, 0.36; P = .050). Thus, we suggest that SDD may be an effective strategy for the prevention of recurrent H. cinaedi bacteremia, especially in high-risk patients such as those receiving anticancer chemotherapy and/or systemic steroids. However, SDD introduces a potential risk of antimicrobial resistance [23] , thus further investigation into the efficacy and risks of SDD is required.
This study had some limitations. First, it was a retrospective study. The clinicians tested blood cultures only if H. cinaedi infection recurred and most patients presented with a fever. Therefore, the true incidence of recurrent H. cinaedi bacteremia could be much higher and remains unknown.
Second, it is difficult to differentiate between reactivation and reinfection when H. cinaedi is isolated from blood cultures during a second episode. Moreover, the definition of recurrent H. cinaedi bacteremia might not be ideal. The results should ideally be evaluated using pulse-field gel electrophoresis or genome sequencing. In our study, median time to recurrence of bacteremia after the completion of antibiotic treatment was 26 days. The second episodes occurred relatively quickly, and we suspected that they represented reactivation rather than reinfection. Third, the drug susceptibility of each H. cinaedi strain was not tested in this study. There are currently no recommended guidelines on drug susceptibility testing for H. cinaedi. The agar dilution method, which is generally used for these strains, is time-consuming and laborious [24, 25] . Some previous reports have indicated that it is difficult to test the drug susceptibility of H. cinaedi using a broth microdilution method because the strains often fail to grow [26] . Recently, Tomida et al established a broth microdilution method for antimicrobial susceptibility testing of H. cinaedi [27] . Currently, drug susceptibility cannot be accurately assessed in the clinical setting. Various antimicrobial agents were administered for the treatment of H. cinaedi bacteremia; however, no significant differences in the prognoses and rates of recurrence among patients treated with the penicillin-, cephem-, carbapenem-, or fluoroquinolone-containing regimen were found. Further investigations into the relationship between drug susceptibility and clinical efficacy are needed.
Last, although we identified factors associated with the recurrence of H. cinaedi bacteremia, this retrospective study was limited because other clinical factors might not have been adequately evaluated. It is possible that H. cinaedi bacteremia and the recurrent infection represent a marker of the severity of a patient's underlying diseases and its associated immunosuppression.
CONCLUSIONS
The 100-day cumulative incidence rate of recurrent H. cinaedi bacteremia was 18.7% in 2 Japanese hospitals. Anticancer chemotherapy and systemic steroids were independent risk factors for recurrent bacteremia. SDD is a potential strategy that could reduce the rate of recurrent bacteremia.
Notes
